Isotopia Molecular Imaging and CPDC Announce Production Agreement for n.c.a. Lu-177

Isotopia Molecular Imaging and CPDC are pleased to announce that they have entered into an agreement for the production and distribution of no-carrier-added Lutetium-177 (n.c.a. Lu-177), a critical medical radioisotope used in the manufacturing of radiopharmaceuticals for treatment of many types of cancer, including neuroendocrine tumors and prostate cancer. The Centre for Probe Development and […]   READ MORE